Dendritic cells induce tolerance to pancreatic islets

树突状细胞诱导胰岛耐受

基本信息

  • 批准号:
    7645165
  • 负责人:
  • 金额:
    $ 34.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

To silence autoimmune disease, we seek a means to expand in mice CD25+ CD4+ foxp3+ regulatory T cells (Treg) that are specific for disease producing autoantigens. We will pursue three themes that have begun through synergisms with Drs. Nussenzweig and Ravetch in this program: 1) The efficiency of antigen presentation in vivo can be greatly increased by targeted delivery of antigen within monoclonal antibodies to uptake receptors on dendritic cell (DCs). 2) A pivotal feature to the outcome of antigen presentation is the state of differentiation or maturation of the DC; this can be enhanced or blocked through selective ligation of activating and inhibitory FcyR respectively. 3) DCs are specialized antigen presenting cells for CD25+ foxp3+ Treg, being able to drive their expansion with maintenance of foxp3 expression and function (5) and to convert CD25- foxp3- T cells into CD25+ foxp3+ T reg (preliminary data). Therefore we will identify DC receptors, subsets and maturation states that are required to control the development and maintenance of antigen-specific T reg in the peripheral tissues of mice. Aim 1 will determine the DC requirements for the expansion of CD25+ CD4+ foxp3+ antigen-specific Treg in vivo, pursuing initial evidence that the 33D1 receptor on CDS- DCs is an effective pathway. Aim 2 will determine the DC requirements for the differentiation of CD25+ CD4+ foxp3+ antigen-specific Treg in vivo from CD25- CD4+ foxpS- progenitors, pursuing initial evidence that the DEC-205 receptor on CD8+ DCs is an effective pathway and that TGFp works in concert with antigen presenting DCs to generate typical antigen-specific foxp3+ T reg. Aim 3 will induce, expand and maintain antigen-specific Tregs from a naive polyclonal T cell repertoire, including capacity of DC-targeting antibodies to ligate activating and inhibitory Feyreceptors. By harnessing the biology of DCs in vivo, particularly by targeting antigens within monoclonal antibodies to uptake receptors expressed on DCs, and by controlling the state of differentiation or maturation of DCs, we will be able to define the priniciples for generating large numbers of disease specific regulatory T cells in intact mice. This should in turn translate into new targeted therapies and products required to control autoimmunity in patients in a much more disease specific manner than has previously been feasible.
为了沉默自身免疫性疾病,我们寻求一种在小鼠中扩增CD 25 + CD 4 + foxp 3+调节性T细胞的方法, (Treg),其特异于疾病产生自身抗原。我们将探讨三个主题, 通过与Nussenzweig和Ravetch博士在该项目中的协同作用:1)抗原的效率 通过在单克隆抗体内靶向递送抗原, 树突状细胞(DC)上的摄取受体。2)抗原呈递结果的关键特征是 DC的分化或成熟状态;这可以通过选择性连接 分别激活和抑制Fc γ R。3)DC是CD 25+的特异性抗原呈递细胞 foxp 3 + Treg,能够在维持foxp 3表达和功能的情况下驱动其扩增(5),以及 将CD 25-foxp 3- T细胞转化为CD 25 + foxp 3 + T reg(初步数据)。因此,我们将识别DC 受体,亚群和成熟状态,需要控制的发展和维护 小鼠外周组织中的抗原特异性T reg。目标1将确定 在体内扩增CD 25 + CD 4 + foxp 3+抗原特异性Treg,追求33 D1 CDS-DCs上的CDS-R受体是一个有效的途径。目标2将确定 从CD 25-CD 4 + foxp 3-祖细胞体内分化CD 25 + CD 4 + foxp 3+抗原特异性Treg, 寻求初步证据表明CD 8 + DC上的DEC-205受体是一种有效途径,并且TGFp 与抗原呈递DC协同工作以产生典型的抗原特异性foxp 3 + T reg. Aim 3将 从幼稚多克隆T细胞库诱导、扩增和维持抗原特异性T细胞,包括 DC靶向抗体连接激活性和抑制性Fe γ受体的能力。通过利用 体内DC生物学,特别是通过将单克隆抗体内的抗原靶向摄取受体 通过控制DC的分化或成熟状态,我们将能够 定义了在完整小鼠中产生大量疾病特异性调节性T细胞的原理。这 应该反过来转化为控制患者自身免疫所需的新的靶向治疗和产品 以一种比以前可行的更加疾病特异性的方式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ralph Marvin Steinman其他文献

Ralph Marvin Steinman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ralph Marvin Steinman', 18)}}的其他基金

DETECTION OF MHC CLASS II PEPTIDES
MHC II 类肽的检测
  • 批准号:
    8361586
  • 财政年份:
    2011
  • 资助金额:
    $ 34.25万
  • 项目类别:
DC-targeted DNA vaccines
DC 靶向 DNA 疫苗
  • 批准号:
    7774820
  • 财政年份:
    2009
  • 资助金额:
    $ 34.25万
  • 项目类别:
FACS
流式细胞仪
  • 批准号:
    7645166
  • 财政年份:
    2008
  • 资助金额:
    $ 34.25万
  • 项目类别:
FACS
流式细胞仪
  • 批准号:
    7300785
  • 财政年份:
    2007
  • 资助金额:
    $ 34.25万
  • 项目类别:
Dendritic cells induce tolerance to pancreatic islets
树突状细胞诱导胰岛耐受
  • 批准号:
    7300779
  • 财政年份:
    2007
  • 资助金额:
    $ 34.25万
  • 项目类别:
HUMAN LYMPHOCYTE ACTIVATION: ROLE OF DENDRITIC CELLS
人类淋巴细胞激活:树突状细胞的作用
  • 批准号:
    7206983
  • 财政年份:
    2005
  • 资助金额:
    $ 34.25万
  • 项目类别:
FACS calibur 4 color modular analytical flow cytometer
FACS calibur 4 色模块化分析流式细胞仪
  • 批准号:
    6577455
  • 财政年份:
    2003
  • 资助金额:
    $ 34.25万
  • 项目类别:
Dendritic Cells: Interfaces with Immunobiology/Medicine
树突状细胞:与免疫生物学/医学的接口
  • 批准号:
    6583501
  • 财政年份:
    2003
  • 资助金额:
    $ 34.25万
  • 项目类别:
CONFERENCE ON DENDRITIC CELLS
树突状细胞会议
  • 批准号:
    6287411
  • 财政年份:
    2001
  • 资助金额:
    $ 34.25万
  • 项目类别:
IMMUNITY TO MELANOMA VIA DENDRITIC CELLS
通过树突状细胞对黑色素瘤产生免疫力
  • 批准号:
    6191790
  • 财政年份:
    2000
  • 资助金额:
    $ 34.25万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 34.25万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 34.25万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 34.25万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.25万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 34.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 34.25万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 34.25万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 34.25万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 34.25万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 34.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了